Selected Publications

Bleiberg BA, Reed-Guy L, Cohen RB, Aggarwal C, Langer CJ, Singh AP, Marmarelis ME.: Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study. Front Oncol 16: 1795920, Apr 2026.

Lukens JN, Riina MD, Weinstein G, MacDuffie E, Ramkissoon A, Baron J, Berger M, Messing I, Gentile M, Maxwell R, Ojerholm E, Swisher-McClure S, Santos AG, Porier K, Basu D, Brody R, Cannady S, Carey R, Chalian A, Newman J, Rajasekaran K, Rassekh C, Shanti R, Cohen RB, Singh A, Sun L, Montone K, Lin A.: Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys Apr 2026.

Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C.: The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing. J Liq Biopsy 12: 100461, Mar 2026.

Qu K, Stalker M, Hwang WT, Cohen RB, Sun L.: Recurrent/metastatic relapse after definitive treatment for HNSCC: timing, patterns, and survival. Front Oncol 16: 1738860, Mar 2026.

Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer 213: 108936, Jan 2026.

Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol 49: 212-218, Nov 2025.

Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B.: Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study. Clin Transl Radiat Oncol 56: 101070, Nov 2025.

Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K.: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. Laryngoscope Aug 2025.

Theodore A Gobillot, Gregory Weinstein, Austin Cao, Jake J Lee, Robert M Brody, Devraj Basu, Bert W O'Malley Jr, D Gregory Farwell, Steven Cannady, Alexander Lin, John Lukens, Michelle Gentile, Jason G Newman, Ara A Chalian, Lova Sun, Deepak Lakshmipathy, Roger B Cohen, Christopher H Rasskeh, Karthik Rajasekaran: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. The Laryngoscope Aug 2025.

Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I.: Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors. Invest New Drugs May 2025.